Pancreatic Cancer Research

ResearcherZhengzhou UniversityActive in the last 2 years

Tiandong Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5465-9797; OpenAlex author ID A5075268456. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 10

  1. Serum autoantibody signatures enable non-invasive early detection of pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.11.017↗
  2. Identification and characterization of MARCO-expressing tumor-associated macrophages in pancreatic ductal adenocarcinoma with pan-cancer relevance. Co-author DOI 10.1038/s41698-026-01293-5↗
  3. Diagnostic valuation of MMP family members as biomarkers for pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1080/17520363.2025.2571394↗
  4. The association between circulating 25-hydroxyvitamin D and pancreatic cancer: a systematic review and meta-analysis of observational studies. Co-author DOI 10.1007/s00394-023-03302-w↗
  5. Coffee and Risk of Pancreatic Cancer: Insights from Two-Sample and Multivariable Mendelian Randomization Analyses. Co-author DOI 10.3390/nu16213723↗
  6. A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-023-03107-1↗
  7. Identification and prognostic analysis of biomarkers to predict the progression of pancreatic cancer patients. First author DOI 10.1186/s10020-022-00467-8↗
  8. Association between plasma 25-hydroxyvitamin D and pancreatic cancer: a systematic review and meta-analysis Co-author DOI 10.21203/rs.3.rs-1968094/v1↗
  9. TSPAN1, TMPRSS4, SDR16C5, and CTSE as Novel Panel for Pancreatic Cancer: A Bioinformatics Analysis and Experiments Validation. First author DOI 10.3389/fimmu.2021.649551↗
  10. Coffee consumption and risk of pancreatic cancer: a systematic review and dose-response meta-analysis. Co-author DOI 10.1080/09637486.2018.1551337↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hua Ye · 5 shared papers, 2022–2026 · strength 1.01
  2. Peng Wang · 5 shared papers, 2019–2024 · strength 0.88
  3. Yajing Shen · 4 shared papers, 2022–2025 · strength 0.80
  4. Hua Ye · 3 shared papers, 2019–2025 · strength 0.46
  5. Mengyuan Lu · 1 shared paper, 2025 · strength 0.25
  6. Li Jiang Sun · 1 shared paper, 2026 · strength 0.24
  7. Yuqi Liu · 1 shared paper, 2026 · strength 0.24
  8. Jicun Zhu · 1 shared paper, 2026 · strength 0.24
  9. Yin Lu · 1 shared paper, 2024 · strength 0.23
  10. Linping Xu · 1 shared paper, 2026 · strength 0.20
  11. Hao Sun · 1 shared paper, 2026 · strength 0.20
  12. Jinxin Miao · 1 shared paper, 2026 · strength 0.20
  13. Wei Li · 1 shared paper, 2022 · strength 0.16
  14. Weijie Wang · 1 shared paper, 2022 · strength 0.16
  15. Jitian Li · 1 shared paper, 2021 · strength 0.12
  16. Guozhong Jiang · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.